About Bioverativ (NASDAQ:BIVV)
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio38.3138686131387
Forward P/E Ratio27.48
Sales & Book Value
Annual Sales$1.17 billion
Price / Sales9.72
Cash Flow$2.88 per share
Price / Cash36.51
Book Value$8.29 per share
Price / Book12.66
Net Income$355.60 million
Return on Equity40.99%
Return on Assets22.79%
Bioverativ (NASDAQ:BIVV) Frequently Asked Questions
What is Bioverativ's stock symbol?
Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."
How were Bioverativ's earnings last quarter?
Bioverativ Inc (NASDAQ:BIVV) announced its quarterly earnings data on Tuesday, February, 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. The biotechnology company had revenue of $328.70 million for the quarter, compared to analysts' expectations of $325.89 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. View Bioverativ's Earnings History.
When will Bioverativ make its next earnings announcement?
Where is Bioverativ's stock going? Where will Bioverativ's stock price be in 2018?
15 equities research analysts have issued twelve-month target prices for Bioverativ's stock. Their predictions range from $47.00 to $80.00. On average, they anticipate Bioverativ's share price to reach $64.00 in the next year. View Analyst Ratings for Bioverativ.
What are Wall Street analysts saying about Bioverativ stock?
Here are some recent quotes from research analysts about Bioverativ stock:
- 1. William Blair analysts commented, "We are dropping coverage of Bioverativ , Inc. following the completion of its acquisition by Sanofi (SNY $39.90). Our final rating on Bioverativ was Market Perform." (3/8/2018)
- 2. According to Zacks Investment Research, "Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. " (1/8/2018)
- 3. Cowen Inc analysts commented, "Bioverativ reported Q2 revenue of $289MM (+38% Y/Y) versus consensus of." (8/4/2017)
Who are some of Bioverativ's key competitors?
Some companies that are related to Bioverativ include Medivation (MDVN), Kite Pharma (KITE), Juno Therapeutics (JUNO), Shire-Nps Pharmaceuticals (NPSP), Auspex Pharmaceuticals (ASPX), Ignyta (RXDX), Clinigen Group (CLIN), Neuroderm (NDRM), Sucampo Pharmaceuticals (SCMP), Raptor Pharmaceutical (RPTP), Cascadian Therapeutics (CASC), Oxford BioMedica (OXB), BioTime (BTX), Biotie Therapies (BITI), Circassia Pharmaceuticals (CIR), MaxCyte (MXCT), Faron Pharmaceuticals Oy (FARN) and Ampio Pharmaceuticals (AMPE).
Who are Bioverativ's key executives?
Bioverativ's management team includes the folowing people:
- Brian S. Posner, Independent Chairman of the Board (Age 55)
- John G. Cox, Chief Executive Officer, Director (Age 54)
- John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
- Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
- Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
- Richard Brudnick, Executive Vice President - Business Development (Age 60)
- Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
- Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
- Alexander J. Denner Ph.D., Independent Director (Age 47)
- Louis J. Paglia, Independent Director (Age 59)
Has Bioverativ been receiving favorable news coverage?
News coverage about BIVV stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioverativ earned a media sentiment score of 0.14 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.45 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Bioverativ's major shareholders?
Bioverativ's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.02%), Clearbridge Investments LLC (3.51%), HealthCor Management L.P. (3.47%), Old Mutual Global Investors UK Ltd. (2.32%), Jackson Square Partners LLC (1.95%) and Woodford Investment Management Ltd (1.80%). Company insiders that own Bioverativ stock include Alexander J Denner, Brian S Posner, Diantha Duvall and Louis J Paglia. View Institutional Ownership Trends for Bioverativ.
Which institutional investors are selling Bioverativ stock?
BIVV stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, American Century Companies Inc., Renaissance Technologies LLC, Wells Fargo & Company MN, HealthCor Management L.P., Arrowstreet Capital Limited Partnership, Franklin Resources Inc. and The Manufacturers Life Insurance Company . View Insider Buying and Selling for Bioverativ.
Which institutional investors are buying Bioverativ stock?
BIVV stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., OppenheimerFunds Inc., Old Mutual Global Investors UK Ltd., APG Asset Management N.V., Acadian Asset Management LLC, Jackson Square Partners LLC, Two Sigma Investments LP and Bank of New York Mellon Corp. Company insiders that have bought Bioverativ stock in the last two years include Alexander J Denner, Brian S Posner and Louis J Paglia. View Insider Buying and Selling for Bioverativ.
How do I buy shares of Bioverativ?
Shares of BIVV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bioverativ's stock price today?
One share of BIVV stock can currently be purchased for approximately $104.98.
How big of a company is Bioverativ?
Bioverativ has a market capitalization of $11.36 billion and generates $1.17 billion in revenue each year. The biotechnology company earns $355.60 million in net income (profit) each year or $2.74 on an earnings per share basis. Bioverativ employs 460 workers across the globe.
How can I contact Bioverativ?
Bioverativ's mailing address is 225 2nd Ave, WALTHAM, MA 02451-1122, United States. The biotechnology company can be reached via phone at +1-781-6634400 or via email at [email protected]
MarketBeat Community Rating for Bioverativ (BIVV)MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bioverativ (NASDAQ:BIVV) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.20||2.19||2.44||2.44|
|Ratings Breakdown: ||0 Sell Rating(s)|
12 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
13 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
|1 Sell Rating(s)|
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$64.00||$63.25||$60.36||$60.36|
|Price Target Upside: ||39.04% downside||38.69% downside||18.91% upside||7.04% upside|
Bioverativ (NASDAQ:BIVV) Consensus Price Target History
Bioverativ (NASDAQ:BIVV) Analyst Ratings History
(Data available from 3/20/2016 forward)
Bioverativ (NASDAQ:BIVV) Earnings History and Estimates Chart
Bioverativ (NASDAQ BIVV) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/2/2018|| || || || || || || || |
|2/13/2018||Q4 2017||$0.75||$0.76||$325.89 million||$328.70 million||View||N/A|
|10/26/2017||Q3 2017||$0.55||$0.80||$285.45 million||$291.60 million||View||N/A|
|8/2/2017||Q2 2017||$0.71||$0.88||$269.00 million||$289.10 million||View||Listen|
|5/3/2017||Q1 2017||$0.62||$0.65||$250.03 million||$259.10 million||View||N/A|
Bioverativ (NASDAQ:BIVV) Earnings Estimates
Current Year EPS Consensus Estimate: $3.82 EPS
Next Year EPS Consensus Estimate: $4.18 EPS
Dividend History for Bioverativ (NASDAQ:BIVV)
No dividend announcements for this company have been tracked by MarketBeat.com
Bioverativ (NASDAQ BIVV) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 97.18%
Bioverativ (NASDAQ BIVV) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/9/2017||Brian S Posner||Director||Buy||1,000||$59.19||$59,190.00||6,693|| |
|8/7/2017||Louis J Paglia||Director||Buy||2,000||$59.70||$119,400.00||5,056|| |
|6/28/2017||Diantha Duvall||Insider||Sell||818||$60.47||$49,464.46||2,128|| |
|5/30/2017||Alexander J Denner||Director||Buy||90,000||$55.93||$5,033,700.00||5,001|| |
|5/26/2017||Louis J Paglia||Director||Buy||2,000||$57.76||$115,520.00||3,056|| |
|5/24/2017||Brian S Posner||Director||Buy||2,000||$53.86||$107,720.00||4,993|| |
Bioverativ (NASDAQ BIVV) News Headlines
Bioverativ (NASDAQ:BIVV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bioverativ (NASDAQ:BIVV) Income Statement, Balance Sheet and Cash Flow Statement
Bioverativ (NASDAQ BIVV) Stock Chart for Tuesday, March, 20, 2018